Beta-blockers may help in COPD

25 May 2010

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blockers, according to a report in the May 24 issue of Archives of Internal Medicine.

According to the journal article, by 2020 COPD (including emphysema and chronic bronchitis) is expected to become the third leading cause of death in the Western world.

Patients with the condition are also prone to develop and die from cardiovascular diseases.

Beta-blockers, used to treat high blood pressure and heart rhythm disorders, are known to improve the survival of patients with cardiovascular disease. However, clinicians avoid use of beta-blockers in patients with COPD because of concerns about adverse effects on the lungs.

Dutch researchers studied data from electronic medical records of 2,230 patients (average age 64.8) with COPD who visited 23 general medical practices between 1996 and 2006. Of these, 560 had COPD at the start of the study and 1,670 developed it during the study period; 665 used beta-blockers and 1,565 did not.

During an average of 7.2 years of follow-up, 686 patients (30.8 percent) died, including 27.2 percent of those who used a beta-blocker compared with 32.3 percent of those who did not use a beta-blocker. In addition, 1,055 patients (47.3 percent) had at least one exacerbation of COPD, including 42.7 percent of those who had used a beta blocker and 49.3 percent of those who did not use a beta-blocker.

Among the subgroup of 1,229 patients without overt cardiovascular disease, 520 (42.3 percent) experienced at least one exacerbation of COPD and 241 (19.6 percent) died. These outcomes were both less likely among the 239 patients (19.4 percent) who used beta-blockers.

“To our knowledge, this is the first observational study that shows that long-term treatment with beta-blockers may improve survival and reduce the risk of an exacerbation of COPD in the broad spectrum of patients with a diagnosis of COPD, including those who have COPD with but, importantly, also without overt cardiovascular comorbidities,” the authors write.

“Whether beta-blockers can also cause beneficial pulmonary [lung] activity and therefore are truly ‘cardiopulmonary’ drugs remains to be proved,” the authors write. Randomized controlled trials to assess the use of beta-blockers in patients with COPD are necessary, they conclude.

In an accompanying editorial, doctors Don D. Sin and S.F. Paul Man of the University of British Columbia and the Providence Heart and Lung Institute, Vancouver, Canada, write although beta-blockers reduce deaths among patients with some cardiovascular conditions by 30 percent to 40 percent, their use “is frequently withheld in patients who have co-existing COPD because clinicians fear that beta-blockers will provoke bronchospasm and induce respiratory failure in these patients.

“Not surprisingly, large epidemiological studies have shown that fewer than one-third of patients with COPD receive beta-blockers after an acute coronary event despite compelling data that they prolong life and improve health outcomes in such patients.”

“The study by Rutten et al provocatively suggests that the use of beta-blockers, contrary to classic teaching, is not only safe but also can prolong survival and reduce exacerbations in COPD, providing new hope for patients with COPD,” the commentators conclude.

“However, before we can fully accept this notion, a large, well-conducted, randomized controlled trial will be needed to confirm these findings. Until then, the data by Rutten and colleagues provides a rationale for the practicing clinicians to use beta-blockers cautiously in their patients with COPD who also have a co-existing cardiovascular condition for which a beta-blocker is required.”

(Arch Intern Med. 2010;170[10]:880-887 and Arch Intern Med. 2010;170[10]:849-850)   

Submit Comment

<< Back